Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 DeficiencyGlobeNewsWire • 05/07/21
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 DeficiencyGlobeNewsWire • 04/29/21
Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical ConferencesGlobeNewsWire • 04/28/21
Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and GenomicsGlobeNewsWire • 04/14/21
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics MeetingGlobeNewsWire • 04/08/21
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/25/21
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical OfficerGlobeNewsWire • 02/04/21
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 DeficiencyGlobeNewsWire • 01/04/21
Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/12/20
Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific OfficerGlobeNewsWire • 10/13/20
Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 09/03/20